Advertisements


Alnylam"s Onpattro approved by FDA to treat polyneuropathy caused by hATTR

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 10th, 2018

Alnylam confirms FDA approves Onpattro to treat polyneuropathy caused by hATTR

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 10th, 2018

Alnylam (ALNY) Gets FDA Nod for First-Ever RNAi Therapeutic

Alnylam (ALNY) receives FDA approval for Onpattro to treat polyneuropathy of hereditary transthy.....»»

Category: dealsSource: nytAug 13th, 2018

Alnylam rare drug gets FDA approval, to cost $345,000 on average

Alnylam Pharmaceuticals Inc.'s rare disease drug Onpattro has been approved by the Food and Drug Administration, marking the first approval of a therapy that employs the RNA interference (RNAi) gene-silencing technique. Onpattro, also called patis.....»»

Category: topSource: marketwatchAug 11th, 2018

Alnylam rare drug gets FDA approval, to cost $345,000 on oaverage

Alnylam Pharmaceuticals Inc.'s rare disease drug Onpattro has been approved by the Food and Drug Administration, marking the first approval of a therapy that employs the RNA interference (RNAi) gene-silencing technique. Onpattro, also called patis.....»»

Category: topSource: marketwatchAug 10th, 2018

FDA approves Alnylam"s Onpattro as hATTR treatment

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 10th, 2018

Alnylam & Medison Partner to Market RNAi Products in Israel

Alnylam (ALNY) partners with Israel's Medison Pharma to commercialize Onpattro and other RNAi pipeline candidates und.....»»

Category: worldSource: nytJan 22nd, 2019

Alnylam, Israel"s Medison partner to commercialize Onpattro, RNAi portfolio

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 21st, 2019

Alnylam Reports Improved Onpattro Sales Going Into A Busy Year

Alnylam Reports Improved Onpattro Sales Going Into A Busy Year.....»»

Category: topSource: seekingalphaJan 8th, 2019

Alnylam (ALNY) Reports Preliminary Onpattro Revenues for Q4

Alnylam (ALNY) reports preliminary revenues for Onpattro for the fourth quarter of 2018, and also provides other update.....»»

Category: personnelSource: nytJan 8th, 2019

Alnylam reports better-than-expected Onpattro revenues, says Piper Jaffray

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 7th, 2019

Alnylam announces unaudited Q4 ONPATTRO revenues of $11M-$12M

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 7th, 2019

Lilly to buy Loxo Oncology for about $8 billion in cancer bet

Eli Lilly and Co said on Monday it would buy Loxo Oncology Inc for about $8 billion in cash, buying into a portfolio of targeted medicines to treat cancers caused by rare gene mutations......»»

Category: topSource: moneycentralJan 7th, 2019

Lilly to buy Loxo Oncology in $8 billion cancer push

Eli Lilly and Co said on Monday it would buy Loxo Oncology Inc for about $8 billion in cash, buying into a portfolio of targeted medicines to treat cancers caused by rare gene mutations......»»

Category: topSource: reutersJan 7th, 2019

Boston startup nabs U.S. approval for app to help treat opioid addicts

The FDA's clearance of the reSET-O app by Pear Therapeutics marks the first time the federal agency has approved a drug-paired digital device to treat a disease......»»

Category: topSource: bizjournalsDec 10th, 2018

A Sluggish Start With Onpattro Is Not What Alnylam Shareholders Needed

A Sluggish Start With Onpattro Is Not What Alnylam Shareholders Needed.....»»

Category: topSource: seekingalphaNov 20th, 2018

New Erectile Dysfunction Treatment Likely to Face Stiff Competition If Approved

The demand for drugs to treat erectile dysfunction has risen to meet the needs of an aging population and to help combat disease-related causes......»»

Category: blogSource: 247wallstNov 8th, 2018

The FDA Approved the First Big New Flu Drug in Almost 20 Years—And Is Approaching a Drug Approval Record

Shionogi and Genentech's Xofluza may treat certain people's .....»»

Category: europeSource: fortuneOct 24th, 2018

Alnylam"s Onpattro highly efficacious, safer than competitor, says Piper Jaffray

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 7th, 2018

US regulators OK updated version of decades-old antibiotic

U.S. regulators have approved a modernized version of a decades-old antibiotic used to treat a number of infections......»»

Category: topSource: foxnewsOct 2nd, 2018

Alnylam launches ONPATTRO in Germany

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 2nd, 2018